No Data
Kazia Therapeutics | 20-F: FY2024 Annual Report
Kazia Therapeutics Secures Nasdaq Compliance
Express News | Kazia Therapeutics -Got Letter From Nasdaq Informing Co Has Regained Compliance With Minimum Bid Price Requirement for Continued Listing
Express News | Kazia Therapeutics Ltd - Full Data From Paxalisib Arm Expected Later This Year
Kazia Therapeutics Announces Granting of Type C Meeting With FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
No Data
No Data